By Laura Anderson | Writer and editor
Final report: Together, we’ve given millions of children a future free of meningitis. Thank you.
After more than a decade of breakthrough work, the Meningitis Vaccine Project (MVP) has reached a final milestone. In December, we transitioned our efforts to our global, country, and local partners and closed our doors. With this shift to local ownership—a longstanding goal—our colleagues will carry our efforts forward, helping the powerful MenAfriVac® vaccine continue to reach families throughout sub-Saharan Africa.
Your support has helped us protect millions of lives, given the world a bold new model for vaccine development, and demonstrated that our shared dedication can change the future for women and children worldwide.
It’s been an exhilarating journey. As MVP’s dedicated supporters, you’ve seen how a unique partnership allowed PATH, the World Health Organization, the Serum Institute of India Ltd., and others around the world to create a safe, effective, and affordable vaccine for meningitis A—in record time and at one-tenth the usual cost of developing a vaccine. You’ve followed along as we’ve conducted the clinical trials that ensure the vaccine’s safety and effectiveness. And you’ve stood with us as we’ve brought it to more communities than many thought possible.
As of this month, the vaccine has reached a staggering 200 million people in 15 countries, with campaigns continuing. And to date, not a single vaccinated person has gotten meningitis.
Together, we’ve stopped a devastating killer in its tracks, freeing millions of people from fear, giving children a new chance to thrive, and transforming global health forever. Thank you!
Want to continue your lifesaving role?
The MVP has closed, but PATH’s innovative work to end health inequity and protect the lives of women and children continues in more than 70 countries—and we need your support. Right now, for example, we’re working to stamp out a disease called Japanese encephalitis (JE) that kills or disables thousands of children every year. To learn more and help us bring a safe, effective vaccine to thousands of vulnerable children, visit our JE project on GlobalGiving.
Or visit PATH’s website at www.path.org to learn how we’re accelerating health solutions worldwide.
The Meningitis Vaccine Project is a partnership between PATH and the World Health Organization. Started in 2001 with funding from the Bill & Melinda Gates Foundation, the mission of MVP is to eliminate meningitis as a public health problem in sub-Saharan Africa through the development, testing, introduction, and widespread use of conjugate meningococcal vaccines. MenAfriVac is a registered trademark of Serum Institute of India Ltd.
Links:
By Laura Anderson | Writer and editor
By Laura Anderson | Writer and Editor
Project reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
If you donate to this project or have donated to this project, you can receive an email when this project posts a report. You can also subscribe for reports without donating.
